Progesterone as an immunomodulatory molecule

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Increased progesterone sensitivity of pregnancy lymphocytes is due to activation-induced appearance of progesterone binding sites in the lymphocytes. Following recognition of fetally derived antigens γ/δ TCR+ cells develop progesterone receptors. Progesterone binding results in the synthesis of a mediator protein named the progesterone-induced blocking factor (PIBF). PIBF by acting on the phospholipase A2 enzyme interferes with arachidonic acid metabolism, induces a Th2 biased immune response, and by controlling NK activity exerts an anti-abortive effect.

Original languageEnglish
Pages (from-to)1037-1048
Number of pages12
JournalInternational Immunopharmacology
Volume1
Issue number6
DOIs
Publication statusPublished - Jun 2001

Fingerprint

Progesterone
Lymphocytes
Phospholipases A2
Progesterone Receptors
Arachidonic Acid
Binding Sites
Antigens
Pregnancy
Enzymes
Proteins
blocking factor

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Progesterone as an immunomodulatory molecule. / Szekeres-Barthó, J.; Barakonyi, A.; Pár, G.; Polgár, B.; Palkovics, T.; Szereday, L.

In: International Immunopharmacology, Vol. 1, No. 6, 06.2001, p. 1037-1048.

Research output: Contribution to journalArticle

@article{0cb615b4bb0148e9b0fb5aa839890b5d,
title = "Progesterone as an immunomodulatory molecule",
abstract = "Increased progesterone sensitivity of pregnancy lymphocytes is due to activation-induced appearance of progesterone binding sites in the lymphocytes. Following recognition of fetally derived antigens γ/δ TCR+ cells develop progesterone receptors. Progesterone binding results in the synthesis of a mediator protein named the progesterone-induced blocking factor (PIBF). PIBF by acting on the phospholipase A2 enzyme interferes with arachidonic acid metabolism, induces a Th2 biased immune response, and by controlling NK activity exerts an anti-abortive effect.",
author = "J. Szekeres-Barth{\'o} and A. Barakonyi and G. P{\'a}r and B. Polg{\'a}r and T. Palkovics and L. Szereday",
year = "2001",
month = "6",
doi = "10.1016/S1567-5769(01)00035-2",
language = "English",
volume = "1",
pages = "1037--1048",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Progesterone as an immunomodulatory molecule

AU - Szekeres-Barthó, J.

AU - Barakonyi, A.

AU - Pár, G.

AU - Polgár, B.

AU - Palkovics, T.

AU - Szereday, L.

PY - 2001/6

Y1 - 2001/6

N2 - Increased progesterone sensitivity of pregnancy lymphocytes is due to activation-induced appearance of progesterone binding sites in the lymphocytes. Following recognition of fetally derived antigens γ/δ TCR+ cells develop progesterone receptors. Progesterone binding results in the synthesis of a mediator protein named the progesterone-induced blocking factor (PIBF). PIBF by acting on the phospholipase A2 enzyme interferes with arachidonic acid metabolism, induces a Th2 biased immune response, and by controlling NK activity exerts an anti-abortive effect.

AB - Increased progesterone sensitivity of pregnancy lymphocytes is due to activation-induced appearance of progesterone binding sites in the lymphocytes. Following recognition of fetally derived antigens γ/δ TCR+ cells develop progesterone receptors. Progesterone binding results in the synthesis of a mediator protein named the progesterone-induced blocking factor (PIBF). PIBF by acting on the phospholipase A2 enzyme interferes with arachidonic acid metabolism, induces a Th2 biased immune response, and by controlling NK activity exerts an anti-abortive effect.

UR - http://www.scopus.com/inward/record.url?scp=0035030936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035030936&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(01)00035-2

DO - 10.1016/S1567-5769(01)00035-2

M3 - Article

C2 - 11407300

AN - SCOPUS:0035030936

VL - 1

SP - 1037

EP - 1048

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 6

ER -